PTC Therapeutics said Tuesday that its treatment for Duchenne muscular dystrophy slowed the loss of muscle function in patients in a randomized clinical trial designed to keep the drug on the market in Europe.
But a separate analysis of the same study data that might allow PTC to seek approval in the U.S. failed to reach statistical significance.
Shares of PTC rose 18% to $33 in early Tuesday trading.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
